
MaxCyte, Inc. (($MXCT)) has held its Q3 earnings call. Read on for the main highlights of the call. MaxCyte’s earnings call carried a strongly positive tone, supported by 49% third-quarter
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| MXCT | MaxCyte | 1.17 | -0.54 | -31.58% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.17 | -31.58% |

MaxCyte, Inc. (($MXCT)) has held its Q3 earnings call. Read on for the main highlights of the call. MaxCyte’s earnings call carried a strongly positive tone, supported by 49% third-quarter

MaxCyte (MXCT) announced that it has entered into a definitive agreement to acquire Akron BioProducts from affiliates of Arcline Investment Management for total consideration of $151.8M. The transaction is expected

Reports Q3 revenue $10.2M including $8.2M of core revenue and $2.0M of SPL Program-related revenue, consensus $7.47M. “Today, we announced our intention to acquire Akron Bio, a transformational moment for

2026 revenue view consists of core revenue of $28M, SPL Program-related revenue of at least $6.5M for the year; SPL Program-related revenue guidance includes both revenue of approximately $4M from

An announcement from MaxCyte ( ($MXCT) ) is now available. On November 9, 2026, MaxCyte entered an agreement to acquire Akron BioProducts LLC, a supplier of GMP-grade reagents and ancillary

MaxCyte, Inc. (MXCT) is scheduled to report 3rd quarter earnings on 11/10/2026, after the market closes. Regarding Q3 estimates, Wall Street analysts expect MaxCyte, Inc. to post earnings of -$0.08

The major averages were lower near noon, pressured by higher Treasury yields as well as the September CPI report, which came in hotter than expected. Headline CPI rose 0.6% month-over-month

“Preliminary third quarter and total second half revenue is ahead of our expectations, and we updated our core business revenue guidance to reflect approximately 15% year-over-year growth in the second

The company said, “Core business revenue of approximately $28 million, compared to prior guidance of $25 million to $27 million. SPL Program-related revenue of approximately $6 million for the year,

MaxCyte (MXCT) announced that it has appointed Sidharth Kapileshwar as Chief Corporate Development Officer. Kapileshwar joins MaxCyte from Danaher (DHR), where he most recently served as Vice President of Innovation
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 16, 2027TBA | $121.84M | $-0.07 | $7.56M | -0.48 | -4.52 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.